Popular Articles
Stretch Mark

$1.3 Million Grant Awarded To LSUHSC To Develop New Cancer Vaccine
Eduardo Davila, PhD, Assistant Professor of Pediatrics, Microbiology, and Immunology at LSU Health Sciences Center New Orleans School of Medicine and Stanley S. Scott Cancer Center, has been awarded a $1.3 million grant over five years by the National Cancer Institute of the National Institutes of Health to develop new immunotherapies, including a vaccine, for cancer. Two years of the research will be supported by the American Recovery and Reinvestment Act (ARRA).
generic viagra online
Pneumococcal Vaccine Reduces Child Deaths In Developing Countries
A new trial has found that pneumococcal vaccine is effective in preventing severe pneumonia, the leading cause of death among children in developing countries. Co-ordinated by the National Institute for Health and Welfare (THL) between 2000 and 2004, a large scale efficacy trial first of its kind in Asia - was carried out in the Philippines to investigate the effect of an investigational pneumococcal vaccine.
News of the day
$7.7B For H1N1 Included In House War-Spending Bill; India Says Developed Countries Can Do More To Prevent Spread
The U.S. House of Representatives on Tuesday narrowly passed a $106 billion war-funding bill, which "included 7.7 billion to help the nation prepare for an outbreak of the H1N1 virus, the so-called swine flu," the Washington Times reports (Rowland, Washington Times, 6/17). The spending bill will now move to the Senate for consideration (Pelofsky, Reuters, 6/16).
Diagnostics

Genomic Medicine Institute Adds Seven Additional Illumina Genome Analyzers To Expand Capacity For Asian 100 Genome Project

Illumina (NASDAQ:ILMN) announced that the Genomic Medicine Institute (GMI) at Seoul National University College of Medicine in Korea, purchased seven additional Illumina Genome AnalyzerIIx sequencing systems, expanding the capacity of their recently established Asian Genome Center to 10 Illumina sequencing systems. "GMI"s decision to add seven additional Genome Analyzers is further validation that our sequencing platform is delivering leading performance with its unmatched rate of daily output, ease of use and proven paired-end sequencing capabilities," said Tim Orpin, general manager of Illumina"s Asia Pacific Region. Dr. Jeong-Sun Seo, director of the Genomic Medicine Institute, and his team, have completed a deep sequencing project of the Korean genome and the work was published online in Nature July 8, 2009. "This publication demonstrates the global competitiveness of GMI"s technological capabilities and provides a practical example of Korean bio-medical excellence," said Dr. Seo. GMI is the second largest Genome Center in Asia and the largest center that focuses exclusively on human genome analysis and its clinical application in Asia. As part of the Asian 100 Genome Project, GMI plans to complete the whole genome analysis of 100 Asian individuals by 2012 and establish an Asian Genome Database with comprehensive genome information specifically targeting Asian populations. About the Illumina Genome Analyzer Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. Generating over 20 Gigabases of sequence data, the Genome Analyzer offers the highest rate of daily output and the simplest and most user-friendly workflow. The Genome Analyzer also offers the broadest set of supported applications, including those used to profile and discover novel transcripts, to create a high-resolution genome-wide map of DNA-protein binding sites and to sequence entire human genomes to greater than 30x coverage. For more information about the Genome Analyzer and to read what customers are doing with Illumina"s sequencing technology, please visit http://www.illumina.com/sequencing. Illumina


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):